SUPPLEMENTARY INFORMATION:

I. Discussion

By letter dated May 5, 2026, Eden filed, pursuant to Section 103 of the Atomic Energy Act of 1954, as amended, and part 50 of title 10 of the Code of Federal Regulations (10 CFR), “Domestic Licensing of Production and Utilization Facilities,” an application for a construction permit for a medical isotope production complex consisting of a non-power, open-pool reactor facility, a separation processing hot cell facility, a target fabrication facility, and a waste packaging, handling, and storage facility (the Eden Isotope Production Complex). This complex would be located near Eunice, Lea County, New Mexico. The reactor facility would use light water as the moderator, and coolant and individual annular low-enriched uranium fueled targets.

The publicly available version of the construction permit application is available in ADAMS under Package Accession No. ML26125A060. Along with other documents, the ADAMS package includes the transmittal letter (ADAMS Accession No. ML26125A061), the preliminary safety analysis report and environmental report (ADAMS Accession No. ML26125A141), and the quality assurance program description (ADAMS Accession No. ML26125A071). The information submitted by Eden includes certain general information such as financial qualifications submitted pursuant to 10 CFR 50.33, “Contents of applications; general information,” certain technical information submitted pursuant to 10 CFR 50.34, “Contents of applications; technical information,” and an environmental report submitted pursuant to 10 CFR part 51, “Environmental Protection Regulations for Domestic Licensing and Related Regulatory Functions.”

Pursuant to Section 189a. of the Atomic Energy Act of 1954, as amended, and the Commission Policy Statement on Mandatory Hearings for Reactor Licensing (published in the Federal Register at 91 FR 34661), notice is hereby given that the uncontested ( i.e., mandatory) hearing will be held on September 29, 2026, starting at 5:30 p.m. Mountain Time in the Eunice Community Center located at 1115 Avenue I, Eunice, NM 88231. Members of the public are invited to attend the hearing. There will be an opportunity for members of the public to ask questions and provide feedback on the application. This is not an opportunity to request a contested hearing, where petitioners can file intervention requests that contain the contentions they wish to litigate pursuant to 10 CFR 2.309, “Hearing requests, petitions to intervene, requirements for standing, and contentions.” The opportunity to request a contested hearing and petition for leave to intervene was noticed on July 16, 2026 (91 FR 43673).

An open house will be held before the hearing begins, from 5 to 5:30 p.m., to give the public an opportunity to speak with the NRC staff. The hearing will then convene at 5:30 p.m. and begin with a presentation by the NRC staff that will explain the review process and provide a brief overview of the application, followed by a comment period of up to 3 hours. During the comment period, the public will be provided an opportunity to speak on the record. Each member of the public will be allowed to speak for no more than 5 minutes at a time, in an effort to ensure that all stakeholders who wish to provide oral comments or ask questions will have the opportunity to do so. The applicant has been made aware of the hearing and was invited to provide a presentation of no more than 30 minutes following the NRC staff presentation.

The hearing record will remain open until October 13, 2026. Further written comments and questions must be submitted to the following email address: EdenEIPC-CPHearing@nrc.gov. ( printed page 51184) In order to be included in the hearing record, written comments and questions must be received by October 13, 2026. The NRC staff will not consider comments or questions received by other means or after the deadline of October 13, 2026. The NRC staff will treat any written comments or questions received consistent with the Commission Policy Statement on Mandatory Hearings for Reactor Licensing.

Authority:42 U.S.C. 2011 et seq.

91 FR 51183